Tonix Pharmaceuticals, Inc.
26 Main Street – Suite 101
Chatham
New Jersey
07928
United States
Website: http://www.tonixpharma.com/
413 articles about Tonix Pharmaceuticals, Inc.
-
Tonix Pharmaceuticals to Present at The National Academies Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures Public Meeting
12/11/2023
Tonix Pharmaceuticals Holding Corp. announced today that Seth Lederman M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at the National Academies of Sciences, Engineering, and Medicine Committee on the Current State of Research, Development, and Stockpiling of Smallpox Medical Countermeasures public meeting on Thursday December 14, 2023.
-
Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity
12/4/2023
Tonix Pharmaceuticals Holding Corp. today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application to support clinical development of TNX-2900 (intranasal potentiated oxytocin), a proprietary magnesium (Mg2+)-enhanced formulation of intranasal oxytocin, to treat Prader-Willi syndrome (PWS) in children and adolescents.
-
Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December 2023
11/28/2023
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company with marketed products and a pipeline of development candidates, announced that Tonix Management will present and host investor meetings at the following December investor conferences.
-
Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder
11/13/2023
Tonix Pharmaceuticals Holding Corp. announced that the first participant was enrolled in an investigator-initiated Phase 2 study of TNX-1900 for improving bone health in children with autism spectrum disorder, named the BOX study, at Massachusetts General Hospital.
-
Tonix Pharmaceuticals’ Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
11/2/2023
Tonix Pharmaceuticals Holding Corp. today announced that the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH), will conduct a Phase 1 clinical trial with TNX-1800 (recombinant horsepox virus, live vaccine),1 Tonix Pharmaceuticals’ vaccine candidate to protect against COVID-19.
-
Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress
10/30/2023
Tonix Pharmaceuticals Holding Corp. announced data from two oral presentations which were delivered recently at the ACS Clinical Congress 2023, and The IPITA, the International Xenotransplantation Association, and the Cell Transplant and Regenerative Medicine Society Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital in October 2023.
-
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs
10/26/2023
Tonix Pharmaceuticals Holding Corp. announced the completion of the clinical phase of the Phase 2 proof-of-concept, double-blind, randomized, placebo-controlled PREVENTION1 study of TNX-19002 as a potential treatment for the prevention of migraine headaches in chronic migraineurs.
-
New Hope for Long COVID Sufferers
10/25/2023
COVID is an acute disease that comes and goes, but for a growing number of people, the sequelae to the infection - the aftereffects - can become a constellation of symptoms called long COVID that may affect sufferers for years, if not a lifetime.
-
Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe
10/19/2023
Tonix Pharmaceuticals Holding Corp. presented data on its horsepox-based live virus vaccine platform in an oral presentation at the World Vaccine Congress Europe being held in Barcelona, Spain, October 16-19, 2023.
-
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models
10/18/2023
Tonix Pharmaceuticals Holding Corp. today announced that a study published in the Journal Nature1 by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in collaboration with biotechnology company, eGenesis, utilized TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) as part of the immune modulating regimen to prevent organ transplant rejection.
-
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder
10/16/2023
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced the completion of the clinical phase of the Phase 2 potential registration-quality, double-blind, randomized, multicenter, placebo-controlled UPLIFT1 study of TNX-601 ER2 (tianeptine hemioxalate extended-release tablets) as a potential treatment for major depressive disorder (MDD).
-
Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference
10/12/2023
Tonix Pharmaceuticals Holding Corp. announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m. ET, and host investor meetings.
-
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe
10/11/2023
Tonix Pharmaceuticals Holding Corp. announced today that Zeil Rosenberg, M.D., M.P.H., Executive Vice President, Medical, Tonix Pharmaceuticals, will present at the World Vaccine Congress Europe on Wednesday, October 18, 2023, at 2:45 p.m. CEST in Barcelona, Spain.
-
Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain
10/4/2023
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that the European Patent Office issued European Patent No. 3242676 to the Company on October 4, 2023.
-
Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering
9/29/2023
The gross proceeds of the offering will be approximately $4.5 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
-
Tonix Pharmaceuticals Announces Proposed Public Offering - September 28, 2023
9/28/2023
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of common stock in a public offering.
-
Tonix Pharmaceuticals Announces DoD Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder
9/27/2023
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, announced that the University of North Carolina Institute for Trauma Recovery has been awarded a $3 million grant from the Department of Defense to investigate the potential of Tonix’s TNX-102 SL to reduce the frequency and severity of adverse effects of acute trauma.
-
Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023
9/21/2023
Tonix Pharmaceuticals Holding Corp. announced a poster presentation showing research results for mTNX-1700 at the Seventh International Cancer Immunotherapy Conference 2023 : Translating Science into Survival, being held September 20-23, 2023, in Milan, Italy.
-
Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress
9/18/2023
Tonix Pharmaceuticals Holding Corp. today announced that David C. Yeomans, Ph.D. presented data relevant to the proposed mechanism of TNX-1900 (intranasal potentiated oxytocin) in treating chronic migraine in a poster and an oral presentation at the 2023 International Headache Congress (IHC), being held September 14-17, 2023, in Seoul, South Korea.
-
Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023
9/14/2023
Tonix Pharmaceuticals Holding Corp. today announced a poster presentation at the Seventh International Cancer Immunotherapy Conference 2023 (CICON23): Translating Science into Survival. The Conference is being held September 20-23, 2023, in Milan, Italy.